Tixagevimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Tixagevimab
- 2196
- azd 8895
- AZD-8895
- azd8895
- AZD8895
- AZD8895 (cell pool material)
- AZD8895 (clonal cell line material)
- azd8895 cell pool material
- cov2 2196
- COV2-2196
- IMMUNOGLOBULIN G1 (240-THREONINE,241-METHIONINE,308-TYROSINE,310-THREONINE,312-GLUTAMIC ACID), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL AZD8895 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AZD8895 .KAPPA.-CHAIN, DIMER
- immunoglobulin g1 240 threonine 241 methionine 308 tyrosine 310 threonine 312 glutamic acid anti severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor binding domain human monoclonal azd8895 gamma 1 chain disulfide with human monoclonal azd8895 kappa chain dimer
- tixagevimab
- Tixagevimab
- tixagevimab [INN]
- TIXAGEVIMAB [JAN]
- TIXAGEVIMAB [USAN]
- Tixagevimab [WHO-DD]
- tixagevimab inn
- tixagevimab jan
- tixagevimab usan
- tixagevimab who dd
- CAS registry numbers
- 2420564-02-7
- ChEMBL ID
- CHEMBL4650265
- RxNorm IDs (RxCUI)
- 2587300
- FDA ingredient codes (UNII)
- F0LZ415Z3B
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- tixagevimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Mechanism
- Spike glycoprotein blocker
- Action type
- Blocker
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein blocker
- Action type
- Blocker
- Target
- Spike glycoprotein
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
Open Targets indications
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05166421
- NCT05321394
- NCT05375760
- NCT05438498
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- Asn-303 $ Asn-303''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-89' $ 23'''-89''' $ 101-106 $ 101''-106'' $ 136'-196' $ 136'''-196''' $ 150-206 $ 150''-206'' $ 216'-226 $ 216'''-226'' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-303 $ Asn-303''
Related records
Trials (6)
- A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
- EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS
- Non-inferiority Trial on Treatments in Early COVID-19
- Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
- Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
- Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
In development for (1)
- COVID-19 Phase 3